237 related articles for article (PubMed ID: 26183297)
1. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martin-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM; ;
J Infect; 2015 Nov; 71(5):561-70. PubMed ID: 26183297
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
3. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.
San Juan R; Yebra M; Lumbreras C; López-Medrano F; Lizasoain M; Meneu JC; Delgado J; Andrés A; Aguado JM
Clin Transplant; 2009; 23(5):666-71. PubMed ID: 19689451
[TBL] [Abstract][Full Text] [Related]
4. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
5. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
7. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
8. Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients.
Limaye AP; La Rosa C; Longmate J; Diamond DJ
Transplantation; 2016 Jan; 100(1):210-6. PubMed ID: 26680375
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
10. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
La Rosa C; Limaye AP; Krishnan A; Blumstein G; Longmate J; Diamond DJ
Transpl Int; 2011 Sep; 24(9):920-31. PubMed ID: 21672050
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
12. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
14. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
Jamal AJ; Husain S; Li Y; Famure O; Kim SJ
Transplantation; 2014 Mar; 97(5):569-75. PubMed ID: 24398852
[TBL] [Abstract][Full Text] [Related]
17. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
Li F; Kenyon KW; Kirby KA; Fishbein DP; Boeckh M; Limaye AP
Clin Infect Dis; 2007 Aug; 45(4):439-47. PubMed ID: 17638191
[TBL] [Abstract][Full Text] [Related]
19. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
20. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
